After pretreatment of human intestinal cell lines with IFN-β and human colon organoids with IFN-β1 and type III IFN, respectively, a protective effect against SARS-CoV-2 infection was observed, resulting in a significantly milder infection (43, 44). This evidence concerns the gene IFNB1 and infection.